Neuraxis, INC (NRXS) Form 10-Q — May 12, 2026
Neuraxis, Inc. reported a 79.5% increase in net sales to $1,607,883 for the three months ended March 31, 2026, compared to $895,655 in the same period of 2025. This growth is attributed to the IB-Stim device's Category I CPT code effective date of January 1, 2026, and broader insurance coverage. The company's gross profit increased by 83.8% to $1,389,517 for the three months ended March 31, 2026, from $756,180 in the same period of 2025.
Key figures
- Eps Beat
- 0
- Revenue
- 1607883
- Total Debt
- 2998156
- Debt Amount
- 100735
- Total Assets
- 8745706
- Cash Position
- 7078659
- Deal Value Usd
- 0
- Interest Rate
- 7.45
- Maturity Date
- June 9, 2026
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 11450045
- Working Capital Surplus
- 5328867
Price after filing
1 day: -4.4%7 days: -12.3%30 days: -17.8%
Close on the filing date to close N calendar days later (from $8.27). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.